Xylyx Bio lands $3M NIH grant, FDA orphan status for bioengineered lung graft
What's the deal? Brooklyn-based Xylyx BioDealroom has a profile for this one. Try Dealroom → has secured a $2,999,266 Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood InstituteDealroom has a profile for this one. Try Dealroom →, part of the National Institutes of HealthDealroom has a profile for this one. Try Dealroom →. The company also won FDA Orphan Drug Designation for Inspirex Lung, its lead candidate to treat lung failure requiring transplantation.
What's the endgame? Inspirex Lung is an investigational human whole-lung graft built to expand the supply of transplantable organs. The company's XC Platform uses xenogeneic cross-circulation — a porcine "bioreactor" — to restore injured donor lungs so they meet standard transplant criteria.
Why now? The two-year, non-dilutive grant funds safety and feasibility work, including proposed first-in-human transplantation studies. Orphan designation can bring tax credits, user-fee exemptions, and up to seven years of market exclusivity after any approval.
The need is stark: more than 75% of donor lungs go unused, often due to acute, reversible injury. "Patients with lung failure often die waiting for a transplant, while most donated lungs are not used," said chief executive officer Andrea Nye.
What could go wrong? The milestones are early. Orphan designation and grant funding do not establish clinical benefit, and the key test remains proving safety and feasibility in people. The field is competitive: in June, the FDA approved United Therapeutics' LungFX ex-vivo perfusion device, which aims to assess and preserve more donor lungs.
The signal: The grant sits in the upper tier of funding events by size, a notable sum for non-dilutive support at this stage. It signals continued public backing for approaches that rehabilitate damaged organs rather than merely preserve them — a potential route to easing a severe transplant shortage, if the clinical evidence follows.
Read more: pr.pineknotnews.com
Image credit: Xylyx Bio
